Agileptin benzoate tablets -Approved for Marketing
Seizing the small tail of July, our another product has obtained approval number - alogliptin benzoate tablets, with approval number H20244565.
Argiliptin benzoate is a dipeptidyl peptidase-4 (DPP-4) inhibitor. Eating can stimulate the intestinal secretion of incretin with increased concentration into the blood stream, slow down the inactivation of DPP-4, and reduce the fasting and postprandial blood glucose in type 2 diabetes patients in a glucose concentration dependent manner. It is a new type of anti diabetes drug. Due to its safety and good tolerability, no significant impact on body weight, and no increased risk of hypoglycemia, DPP-4 inhibitors have become one of the key tracks for major pharmaceutical companies to develop hypoglycemic drugs.
